NantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

6 years ago
Anonymous $2WKDXfy9lA

https://www.businesswire.com/news/home/20180602005025/en/

CHICAGO--(BUSINESS WIRE)--Jun 2, 2018--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC). This will be presented during the head and neck cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“We’re excited to share our analysis on a potential therapy for a form of cancer that rarely responds to chemotherapy or targeted therapy,” said Patrick Soon-Shiong, MD, founder of NantWorks. “There is no standard therapy for advanced ACC, so this is an exciting step toward possibly using comprehensive molecular profiling to help treat patients of this rare secretory gland cancer.”